Swiss National Bank Raises Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Swiss National Bank increased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 12.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 149,600 shares of the company’s stock after acquiring an additional 16,500 shares during the quarter. Swiss National Bank’s holdings in IDEAYA Biosciences were worth $3,845,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Daiwa Securities Group Inc. grew its stake in IDEAYA Biosciences by 44.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock worth $72,000 after purchasing an additional 853 shares in the last quarter. Candriam S.C.A. grew its position in shares of IDEAYA Biosciences by 14.0% during the 4th quarter. Candriam S.C.A. now owns 1,071,825 shares of the company’s stock worth $27,546,000 after buying an additional 131,385 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of IDEAYA Biosciences during the fourth quarter valued at $431,000. Arizona State Retirement System raised its holdings in shares of IDEAYA Biosciences by 12.4% in the fourth quarter. Arizona State Retirement System now owns 22,049 shares of the company’s stock valued at $567,000 after acquiring an additional 2,436 shares in the last quarter. Finally, Aigen Investment Management LP purchased a new stake in IDEAYA Biosciences in the fourth quarter worth about $280,000. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Price Performance

Shares of NASDAQ:IDYA opened at $18.01 on Wednesday. The business’s 50-day moving average is $21.12 and its 200 day moving average is $26.17. IDEAYA Biosciences, Inc. has a 1 year low of $16.95 and a 1 year high of $44.42. The firm has a market capitalization of $1.58 billion, a P/E ratio of -5.46 and a beta of 0.76.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $7.00 million. On average, analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Ratings Changes

IDYA has been the topic of a number of research reports. Wedbush reissued an “outperform” rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Stephens reissued an “overweight” rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.